Researchers from the the Monash University in Australia offer new hope to thousands of people who experience heart attacks and heart failure - one of the major causes of death worldwide.
They showed new insights into a specific protein belonging to the family of G protein-coupled receptors (GPCRs).
After successfully combining two molecules, they say they are a step closer to creating a brand new class of drug that is more targeted and could possess minimal side effects.
Almost half of all current medications available use GPCRs to achieve their therapeutic effect.
Current GPCR drugs work either by fully activating or completely blocking receptors, treating the protein like a simple "on-off" switch.
The new research discovered alternative recognition sites on GPCRs that can be targeted by drugs to fine-tune the behaviour of the protein, basically converting the "on-off" switch into a "dimmer switch".
"Correct dosage has been a serious challenge in clinical trials for A1 receptor drugs. The consequences are serious; a dosage that is too high can stop the heart from beating. Too low, and the drug fails to prevent cell damage. Getting this balance right has been a big problem," said researcher Peter Scammells.
The study was published in the journal PNAS.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
